Holen Sie sich die Stockscreener-App
27.81
2.92%
0.79
Handel nachbörslich:
27.81
Schlusskurs vom Vortag:
$27.02
Offen:
$27.36
24-Stunden-Volumen:
499.45K
Relative Volume:
0.76
Marktkapitalisierung:
$1.83B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-137.95M
KGV:
-11.02
EPS:
-2.5226
Netto-Cashflow:
$-107.11M
1W Leistung:
+2.43%
1M Leistung:
+3.50%
6M Leistung:
+65.83%
1J Leistung:
+136.68%
1-Tages-Spanne:
$27.36
$28.92
1-Wochen-Bereich:
$26.68
$28.92
52-Wochen-Spanne:
$9.57
$30.99
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Firmenname
Bicara Therapeutics Inc
Sektor
Branche
Telefon
617-468-4219
Adresse
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
27.81 | 1.78B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Eingeleitet | BofA Securities | Buy |
| 2026-01-29 | Eingeleitet | Citizens JMP | Mkt Perform |
| 2026-01-08 | Eingeleitet | BTIG Research | Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Neutral |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Eingeleitet | Wells Fargo | Underweight |
| 2025-02-06 | Eingeleitet | Wedbush | Outperform |
| 2024-12-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-08 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
BlackRock (BCAX holder) discloses 5.4% Bicara Therapeutics stake on Schedule 13G - Stock Titan
Bicara Therapeutics Inc (BCAX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bicara Therapeutics Inc (BCAX) Balance Sheet - TradingKey
Bicara Therapeutics Inc (BCAX) Income Statement - TradingKey
Bicara Therapeutics Inc (BCAX) Cash Flow - TradingKey
Bicara Therapeutics Inc (BCAX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bicara Therapeutics Inc (BCAX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BCAX|Bicara Therapeutics Inc|Price:27.020|Chg%:-0.710 - TradingKey
Bicara Therapeutics Inc (BCAX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bicara Therapeutics (BCAX) Hovers Near Support Amid Modest DeclineProfit Surge Picks - dars.gov.et
Bicara Therapeutics (BCAX) Corporate presentation Summary - Quartr
Bicara Therapeutics (BCAX) Proxy filing Summary - Quartr
Bicara Therapeutics (BCAX) Study update Summary - Quartr
Bicara Therapeutics (BCAX) Q1 2026 earnings summary - Quartr
Form 4 Bicara Therapeutics Inc For: 14 July By Investing.com - Investing.com South Africa
Bicara Therapeutics CEO Claire Mazumdar disposes of $284k in stock - Investing.com Nigeria
Bicara Therapeutics CEO Claire Mazumdar disposes of $284k in stock By Investing.com - Investing.com India
Form 4 Bicara Therapeutics Inc For: 14 July - Investing.com India
Bicara Therapeutics (BCAX) CEO exercises options and sells 10,000 shares under 10b5-1 plan - Stock Titan
Enterprise value to revenue forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Extended Trial Data And Insider Sale Could Be A Game Changer For Bicara Therapeutics (BCAX) - Sahm
Bicara therapeutics president & COO sells $833k in stock By Investing.com - Investing.com India
Bicara Therapeutics CFO Hyep Ivan sells $807k in stock By Investing.com - Investing.com India
Form 144 Bicara Therapeutics Inc. For: 10 July By Investing.com - Investing.com Nigeria
Enterprise value to EBIT forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Form 4 Bicara Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Bicara Therapeutics CFO Hyep Ivan sells $807k in stock - Investing.com
Bicara therapeutics president & COO sells $833k in stock - Investing.com
Bicara Therapeutics Insider Sold Shares Worth $833,129, According to a Recent SEC Filing - marketscreener.com
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics (BCAX) COO exercises options, sells 28,750 shares under plan - Stock Titan
Price to sales forward of Bicara Therapeutics Inc. – BOATS:BCAX - TradingView
Price to book forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Form 144 BICARA THERAPEUTICS INC. For: 8 July By Investing.com - Investing.com Nigeria
Form 144 Bicara Therapeutics Inc. For: 8 July By Investing.com - Investing.com Nigeria
BCAX (NASDAQ) insider sales: 50,000-share option exercise set for 07/08/2026 - Stock Titan
Sale notice: 28,750 shares disclosed by BCAX (NASDAQ: BCAX) - Stock Titan
BCAX (NASDAQ) affiliate files Rule 144; past sales of 9,200 shares noted - Stock Titan
Bicara Therapeutics (BCAX) Piper Sandler 37th Annual Healthcare Conference Summary - Quartr
Form 144 BICARA THERAPEUTICS INC. For: 7 July By Investing.com - Investing.com Nigeria
Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):